Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Jmk2454on Aug 02, 2019 5:57pm

51 Views

Post# 29990626

RE:RE:RE:RE:RE:RE:ENJOY THE WEEKEND

Macmasterjr303 wrote:

GoldmansSocks wrote:

Macmasterjr303 wrote:
Stock house just emailed me, he is banned for 7 days

Oh perfect. Thank you. Did they mention if they will be keeping an eye on this? He will be back for sure.

Pm you the email. Oh yes he will be back... I used to stay out of the bs on this board, but I got tired of seeing him post and trash the reputation of the stock. I will rip on him any chance I get. Think I may have actually flustered him today :D Enjoy the weekend! Kly longs